A5076933986- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Advanced biosensing and bioanalysis techniques
- Virus-based gene therapy research
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Nanoparticle-Based Drug Delivery
- RNA Interference and Gene Delivery
- Immunotherapy and Immune Responses
- Protein Degradation and Inhibitors
- Cell death mechanisms and regulation
- Nanowire Synthesis and Applications
- Neuroendocrine Tumor Research Advances
- Bacillus and Francisella bacterial research
- SARS-CoV-2 and COVID-19 Research
- Peptidase Inhibition and Analysis
- Nanoplatforms for cancer theranostics
- MicroRNA in disease regulation
- Multiple Myeloma Research and Treatments
- interferon and immune responses
- Galectins and Cancer Biology
- Cancer Research and Treatments
- Lung Cancer Research Studies
Rutgers, The State University of New Jersey
2019-2025
Tarbiat Modares University
2016-2022
Baqiyatallah University of Medical Sciences
2016
Introduction The Fc region of monoclonal antibodies (mAbs) interacts with the CD16a receptor on natural killer (NK) cells “low affinity” and selectivity”. This low affinity/selectivity interaction results in not only suboptimal anticancer activity but also induction adverse effects. NK binds to antibody-coated cells, leading antibody-dependent cell-mediated cytotoxicity (ADCC). Recent clinical data have shown that increased binding affinity between mAb is responsible for significantly...
Background In a prior report, we detailed the isolation and engineering of bispecific killer cell engager, referred to as BiKE:E5C1. The BiKE:E5C1 exhibits high affinity/specificity for CD16a activating receptor on natural (NK) cells human epidermal growth factor 2 (HER2) cancer cells. vitro studies have demonstrated that can activate NK induce killing HER2+ ovarian breast cells, surpassing performance best-in-class monoclonal antibody, Trazimera (trastuzumab). To advance this BiKE...
Synergistic effect of combined antibodies targeting distinct epitopes a particular tumour antigen has encouraged some clinical trial studies and is now considered as an effective platform for cancer therapy. Providing several advantages over conventional antibodies, variable domain heavy chain (VHH) major tools in diagnostic therapeutic applications. Active liposomal drugs promising strategy, resulting enhanced binding improved cytotoxicity cells. In the present study, we produced four...
Background: Puma is a highly robust pro-apoptotic protein. The protein becomes activated by p53 ensuing beyond-repair DNA damage. Downregulation of SIRT 1, miR-128, elevates that foment indirectly. Objectives: In the present study, we used two-expression Adeno-Associated Virus (AAV) system for co-expression miR-128 and in order to evaluate apoptotic response; both tumor normal cells, respectively. Materials Methods: Three recombinant AAVs constructs were generated. First rAAV bearing under...
Objective: The aim of this study was to formulate fluorescent-labeled targeted immunoliposome visualize the delivery and distribution drugs in real-time. Methods: In study, liposomes were decorated with anti-HER2 VHH or Herceptin improve monitoring intracellular drug tumor cell tracking minimal side effects. conjugation efficiency antibodies analyzed by SDS-PAGE silver staining. addition, physicochemical characterization performed using DLS TEM. Finally, confocal microscopy visualized...
Cancerous cells proliferate as fast possible without a proper surveillance system. This rapid cell division leads to enormous mutation rates, which help tumor establish.This study evaluated the potential of inducing apoptosis using Noxa and Puma in hepatocarcinoma line.The current generated two recombinant lentiviruses, pLEX-GCN pLEX-GCP, bearing Puma, respectively. Transduction both genes (HepG2) was verified fluorescent microscopic analysis, western blotting, quantitative real-time...
Lentiviral gene delivery is now considered as a major candidate in the future of cancer therapy. To avoid common side-effects associated with methods therapy, survivin promoter shows great promise due to its high expression level multiple cancers. In this research, using 2A peptide, Noxa was coexpressed hemagglutinin neuraminidase (HN) driven by (Surp). Coding genes and HN were connected upstream downstream peptide SOE PCR. After cloning Noxa-2A-HN Surp into lentiviral vector, final...
We previously reported the structure, affinity, and anticancer activity of a bivalent bispecific natural killer cell engager (BiKE) composed one anti-CD16a VHH anti-HER2 fused via linker. In this study, we explored engineering tetravalent BiKE by fusing two VHHs in tandem, using as template. The was genetically engineered, its tertiary structure predicted silico modeling. antigen binding affinity were assessed ELISA, flow cytometry, biolayer interferometry. ability BiKEs to kill cancer cells...